TW200800141A - HFC solution formulations containing salbutamol hydrochloride or salbutamol citrate - Google Patents
HFC solution formulations containing salbutamol hydrochloride or salbutamol citrate Download PDFInfo
- Publication number
- TW200800141A TW200800141A TW095129480A TW95129480A TW200800141A TW 200800141 A TW200800141 A TW 200800141A TW 095129480 A TW095129480 A TW 095129480A TW 95129480 A TW95129480 A TW 95129480A TW 200800141 A TW200800141 A TW 200800141A
- Authority
- TW
- Taiwan
- Prior art keywords
- acid
- salbutamol
- aerosol solution
- hfc
- solution formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 238000009472 formulation Methods 0.000 title claims abstract description 66
- 229960002052 salbutamol Drugs 0.000 title claims abstract description 45
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 title claims abstract description 42
- OWNWYCOLFIFTLK-UHFFFAOYSA-N 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;hydron;chloride Chemical compound Cl.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 OWNWYCOLFIFTLK-UHFFFAOYSA-N 0.000 title claims abstract description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 title claims abstract description 11
- 239000002253 acid Substances 0.000 claims abstract description 42
- 239000000443 aerosol Substances 0.000 claims abstract description 40
- 239000003380 propellant Substances 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- 239000006184 cosolvent Substances 0.000 claims abstract description 19
- 239000013543 active substance Substances 0.000 claims abstract description 12
- 150000007524 organic acids Chemical class 0.000 claims abstract description 11
- 150000007522 mineralic acids Chemical class 0.000 claims abstract description 9
- 150000002894 organic compounds Chemical class 0.000 claims abstract description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 45
- -1 salbutamol alkoxide Chemical class 0.000 claims description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 7
- WXGNWUVNYMJENI-UHFFFAOYSA-N 1,1,2,2-tetrafluoroethane Chemical compound FC(F)C(F)F WXGNWUVNYMJENI-UHFFFAOYSA-N 0.000 claims description 6
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- RWRIWBAIICGTTQ-UHFFFAOYSA-N difluoromethane Chemical compound FCF RWRIWBAIICGTTQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 229960001361 ipratropium bromide Drugs 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 239000000812 cholinergic antagonist Substances 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical group O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 229910017604 nitric acid Inorganic materials 0.000 claims description 3
- WGZYQOSEVSXDNI-UHFFFAOYSA-N 1,1,2-trifluoroethane Chemical compound FCC(F)F WGZYQOSEVSXDNI-UHFFFAOYSA-N 0.000 claims description 2
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 claims description 2
- 150000004703 alkoxides Chemical class 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229960001888 ipratropium Drugs 0.000 claims description 2
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 229940127230 sympathomimetic drug Drugs 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 6
- 229940071648 metered dose inhaler Drugs 0.000 claims 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 claims 1
- 229960004134 propofol Drugs 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 44
- 239000000243 solution Substances 0.000 description 26
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 20
- 229940102396 methyl bromide Drugs 0.000 description 17
- 235000019441 ethanol Nutrition 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 150000002431 hydrogen Chemical class 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000012453 solvate Substances 0.000 description 7
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 4
- CHRMMMLUWHPZAH-UHFFFAOYSA-N 7-methoxyquinazoline Chemical compound C1=NC=NC2=CC(OC)=CC=C21 CHRMMMLUWHPZAH-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 229940039009 isoproterenol Drugs 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 150000003505 terpenes Chemical class 0.000 description 4
- 235000007586 terpenes Nutrition 0.000 description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- XQJMXPAEFMWDOZ-UHFFFAOYSA-N 3exo-benzoyloxy-tropane Natural products CN1C(C2)CCC1CC2OC(=O)C1=CC=CC=C1 XQJMXPAEFMWDOZ-UHFFFAOYSA-N 0.000 description 2
- PYUGFOWNYMLROI-KPKJPENVSA-N 8-[(e)-2-[4-[4-(4-fluorophenyl)butoxy]phenyl]ethenyl]-2-(2h-tetrazol-5-yl)chromen-4-one Chemical compound C1=CC(F)=CC=C1CCCCOC(C=C1)=CC=C1\C=C\C1=CC=CC2=C1OC(C=1NN=NN=1)=CC2=O PYUGFOWNYMLROI-KPKJPENVSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical compound C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 2
- QIZDQFOVGFDBKW-DHBOJHSNSA-N Pseudotropine Natural products OC1C[C@@H]2[N+](C)[C@H](C1)CC2 QIZDQFOVGFDBKW-DHBOJHSNSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 239000000150 Sympathomimetic Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000013011 aqueous formulation Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 125000001207 fluorophenyl group Chemical group 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- CRSOQBOWXPBRES-UHFFFAOYSA-N neopentane Chemical compound CC(C)(C)C CRSOQBOWXPBRES-UHFFFAOYSA-N 0.000 description 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- HNJBQZPKNKFLFM-CBEJNMEVSA-N (4s,4ar,7s,7ar,12bs)-7,9-dihydroxy-3-methyl-1,2,4,4a,7,7a-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-13-one Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3C(=O)C5=CC=C4O HNJBQZPKNKFLFM-CBEJNMEVSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- RPWQHIKNNUCMGO-UHFFFAOYSA-N 1,1,1,2-tetrafluorodecane Chemical group C(CCCCCCC)C(C(F)(F)F)F RPWQHIKNNUCMGO-UHFFFAOYSA-N 0.000 description 1
- UJPMYEOUBPIPHQ-UHFFFAOYSA-N 1,1,1-trifluoroethane Chemical compound CC(F)(F)F UJPMYEOUBPIPHQ-UHFFFAOYSA-N 0.000 description 1
- RWRHXNXYHWXCCL-UHFFFAOYSA-N 1,1-difluorodecane Chemical compound CCCCCCCCCC(F)F RWRHXNXYHWXCCL-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- LITNEAPWQHVPOK-FFSVYQOJSA-N 2(1h)-pyrimidinone, 5-[3-[(1s,2s,4r)-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl]tetrahydro- Chemical compound C1=C(O[C@@H]2[C@H]3CC[C@H](C3)C2)C(OC)=CC=C1C1CNC(=O)NC1 LITNEAPWQHVPOK-FFSVYQOJSA-N 0.000 description 1
- ODELFXJUOVNEFZ-UHFFFAOYSA-N 2,2-diphenylpropanoic acid Chemical compound C=1C=CC=CC=1C(C(O)=O)(C)C1=CC=CC=C1 ODELFXJUOVNEFZ-UHFFFAOYSA-N 0.000 description 1
- LVNVLQIXMBTMPH-UHFFFAOYSA-N 2,3-dichlorothiophene Chemical compound ClC=1C=CSC=1Cl LVNVLQIXMBTMPH-UHFFFAOYSA-N 0.000 description 1
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- PDBUTMYDZLUVCP-UHFFFAOYSA-N 3,4-dihydro-1,4-benzoxazin-2-one Chemical compound C1=CC=C2OC(=O)CNC2=C1 PDBUTMYDZLUVCP-UHFFFAOYSA-N 0.000 description 1
- DDYUBCCTNHWSQM-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(N)=O)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 DDYUBCCTNHWSQM-UHFFFAOYSA-N 0.000 description 1
- KLPQJJKXRIDASJ-UHFFFAOYSA-N 3-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]-N-ethyl-8-propan-2-yl-7H-purin-6-imine Chemical compound CCN=C1C2=C(N=C(N2)C(C)C)N(C=N1)CC3=CC(=C(C=C3)OC)OC4CCCC4 KLPQJJKXRIDASJ-UHFFFAOYSA-N 0.000 description 1
- ULMFXAMQUGLVGA-LJQANCHMSA-N 3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methyl-n-[(2r)-4,4,4-trifluoro-2-methylbutyl]indole-5-carboxamide Chemical compound C=1C=C(CC=2C3=CC(=CC=C3N(C)C=2)C(=O)NC[C@H](C)CC(F)(F)F)C(OC)=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1C ULMFXAMQUGLVGA-LJQANCHMSA-N 0.000 description 1
- LIXBJWRFCNRAPA-NSHDSACASA-N 4-[(1r)-2-(tert-butylamino)-1-hydroxyethyl]-3-chlorophenol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C=C1Cl LIXBJWRFCNRAPA-NSHDSACASA-N 0.000 description 1
- UTUUPXBCDMQYRR-HSZRJFAPSA-N 4-[(2r)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine Chemical compound COC1=CC=C([C@H](CC=2C=CN=CC=2)C=2C=CC=CC=2)C=C1OC1CCCC1 UTUUPXBCDMQYRR-HSZRJFAPSA-N 0.000 description 1
- LIXBJWRFCNRAPA-UHFFFAOYSA-N 4-[2-(tert-butylamino)-1-hydroxyethyl]-3-chlorophenol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C=C1Cl LIXBJWRFCNRAPA-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- WWFNYNQCBVIXJO-UHFFFAOYSA-N 7-(oxolan-2-ylmethoxy)quinazoline Chemical compound C=1C=C2C=NC=NC2=CC=1OCC1CCCO1 WWFNYNQCBVIXJO-UHFFFAOYSA-N 0.000 description 1
- FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- WGRXPNXGRDKBMZ-UHFFFAOYSA-N C(CCCCCCCCC)OC1=CC=C2C=NC=NC2=C1 Chemical compound C(CCCCCCCCC)OC1=CC=C2C=NC=NC2=C1 WGRXPNXGRDKBMZ-UHFFFAOYSA-N 0.000 description 1
- QGBIFMJAQARMNQ-QISPFCDLSA-N C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(SC)[C@@]2(C)C[C@@H]1O Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(SC)[C@@]2(C)C[C@@H]1O QGBIFMJAQARMNQ-QISPFCDLSA-N 0.000 description 1
- 229940127597 CGRP antagonist Drugs 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- ZKZAIRRKDTUCRZ-UHFFFAOYSA-N OC1=CC=CC=2C=CC=3N=C4C=CC=CC4=NC=3C=21 Chemical compound OC1=CC=CC=2C=CC=3N=C4C=CC=CC4=NC=3C=21 ZKZAIRRKDTUCRZ-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 241000334993 Parma Species 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical class C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 description 1
- RVCSYOQWLPPAOA-CVPHZBIISA-M [(5s)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride Chemical compound [Cl-].[N+]12([C@H]3CCC2CC(C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 RVCSYOQWLPPAOA-CVPHZBIISA-M 0.000 description 1
- CDKNUFNIFGPFSF-AYVLZSQQSA-N [(8s,9s,10r,11s,13s,14s,17r)-11-hydroxy-10,13-dimethyl-3-oxo-17-(2-propanoylsulfanylacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CSC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O CDKNUFNIFGPFSF-AYVLZSQQSA-N 0.000 description 1
- WKHOPHIMYDJVSA-UHFFFAOYSA-N [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate Chemical compound CC(C)C(=O)OC1=CC(OC(=O)C(C)C)=CC(C(O)CNC(C)(C)C)=C1 WKHOPHIMYDJVSA-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- GVTLDPJNRVMCAL-UHFFFAOYSA-N arofylline Chemical compound C1=2N=CNC=2C(=O)N(CCC)C(=O)N1C1=CC=C(Cl)C=C1 GVTLDPJNRVMCAL-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229950006944 atizoram Drugs 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- WURBFLDFSFBTLW-UHFFFAOYSA-N benzil Chemical compound C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 WURBFLDFSFBTLW-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- TXKAQZRUJUNDHI-UHFFFAOYSA-K bismuth tribromide Chemical compound Br[Bi](Br)Br TXKAQZRUJUNDHI-UHFFFAOYSA-K 0.000 description 1
- 229960004620 bitolterol Drugs 0.000 description 1
- FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 description 1
- 229950008847 broxaterol Drugs 0.000 description 1
- JBRBWHCVRGURBA-UHFFFAOYSA-N broxaterol Chemical compound CC(C)(C)NCC(O)C1=CC(Br)=NO1 JBRBWHCVRGURBA-UHFFFAOYSA-N 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N carbostyril Natural products C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 229960001386 carbuterol Drugs 0.000 description 1
- KEMXXQOFIRIICG-UHFFFAOYSA-N carbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(NC(N)=O)=C1 KEMXXQOFIRIICG-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- FNUZASGZEHGWQM-RJRMRWARSA-M flutropium bromide Chemical compound C[N@+](CCF)([C@H](CC1)C2)[C@@H]1C[C@H]2OC(C(C1=CC=CC=C1)(C1=CC=CC=C1)O)=O.[Br-] FNUZASGZEHGWQM-RJRMRWARSA-M 0.000 description 1
- 229950008319 flutropium bromide Drugs 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- NDJKXXJCMXVBJW-UHFFFAOYSA-N heptadecane Chemical compound CCCCCCCCCCCCCCCCC NDJKXXJCMXVBJW-UHFFFAOYSA-N 0.000 description 1
- 229960000708 hexoprenaline Drugs 0.000 description 1
- OXLZNBCNGJWPRV-UHFFFAOYSA-N hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 description 1
- GVLGAFRNYJVHBC-UHFFFAOYSA-N hydrate;hydrobromide Chemical compound O.Br GVLGAFRNYJVHBC-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229950002451 ibuterol Drugs 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 229960004078 indacaterol Drugs 0.000 description 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229950008204 levosalbutamol Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- JSJCTEKTBOKRST-UHFFFAOYSA-N mabuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 JSJCTEKTBOKRST-UHFFFAOYSA-N 0.000 description 1
- 229950004407 mabuterol Drugs 0.000 description 1
- 235000019671 masking sweet taste Nutrition 0.000 description 1
- 229950001737 meluadrine Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- 125000006611 nonyloxy group Chemical group 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001609 oxitropium bromide Drugs 0.000 description 1
- LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960002288 procaterol Drugs 0.000 description 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
- WGWKNMLSVLOQJB-UHFFFAOYSA-N propan-2-ylazanium;bromide Chemical compound Br.CC(C)N WGWKNMLSVLOQJB-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- PQNAQXGHIIRKLV-UHFFFAOYSA-N quinolin-2-one Chemical compound C1=C[CH]C2=NC(=O)C=CC2=C1 PQNAQXGHIIRKLV-UHFFFAOYSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960001634 ritodrine Drugs 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 description 1
- 229950004432 rofleponide Drugs 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- HTJXMOGUGMSZOG-UHFFFAOYSA-N tiaramide Chemical compound C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 HTJXMOGUGMSZOG-UHFFFAOYSA-N 0.000 description 1
- 229950010302 tiaramide Drugs 0.000 description 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- JACRWUWPXAESPB-UHFFFAOYSA-M tropate Chemical compound OCC(C([O-])=O)C1=CC=CC=C1 JACRWUWPXAESPB-UHFFFAOYSA-M 0.000 description 1
- 229960001530 trospium chloride Drugs 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
- C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
- C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
200800141 九、發明說明: 【發明所屬之技術領域】 本發明係關於一種包含沙丁胺醇之酸加成鹽之穩定氣溶 膠溶液調配物,其適用於經定劑量吸入器(MDI)投藥。更特 k 定言之,本發明係關於一種包含上述沙丁胺醇之鹽之一 、 者、較佳為鹽酸沙丁胺醇或檸檬酸沙丁胺醇、更佳為先前 提及之該兩種鹽之一者與一或多種其他藥用活性物質連同 作為推進劑之環境上安全之氫氟碳(HFC)、共溶劑(較佳有 • 機化合物作為共溶劑)及無機酸或有機酸之組合的溶液調 配物。 【先前技術】 沙丁胺醇為高度有效之β-擬交感神經藥劑,其可用於仏 療呼吸疾病,尤其為COPD(慢性阻塞性肺病)及哮喘。術: 沙丁胺醇係指游離胺鹼。其具有以下化學結構·
Pharmacopoeia) 〇 詳 — 貝過兮經吸入法投藥。除以 之可吸入粉末形式投與氣管細" 胞溶解性活性
為治療上述疾患,該活性物質適合經 包含活性物質之可吸入粉末形式措盥备 化合物外,亦 藉由加壓定 113089.doc 200800141 於療法中,諸如在治療障礙性氣管疾病及哮喘中。與經口 投藥相比,吸入法提供更快速之起始作用時間,同時最小 化系統性副作用。氣溶膠調配物可藉由經口吸入法或藉由 局部塗覆至鼻黏膜來投藥。 用於經加壓MDI進行氣溶膠投藥之調配物可為溶液或懸 浮液。溶液調配物提供之優點為完全溶解於推進劑媒劑之 藥物及賦形劑本質上係均質的。溶液調配物亦排除與懸浮 液調配物相關之物理穩定性問題且從而保證更相容之均一 劑量之投藥而亦不需要界面活性劑。 氣溶膠溶液調配物經由加壓MDIi投藥取決於其製造中 所使用之推進劑系統之推進力。推進劑通常含有氟氯碳 (CFC)之混合物以提供所要溶解度、蒸氣壓及調配物穩定 性。然而,因為近年來已確定CFC因有助於耗盡地球之臭 氧層而具有環境缺點,所以吾人希望以環境上安全之氫氟 碳(HFC)推進劑或其他非氯化推進劑代替氣溶膠吸入調配 物中之環境上有害的CFC推進劑。 舉例而言,美國專利第4,174,295號揭示由HFC組合(亦可 包含飽和烴組份)組成之推進劑系統適用於諸如黏發劑、抗 汗產品、香料、除臭劑、油漆、殺昆蟲劑及其類似物之家 居產品之應用領域的用途。 此項技術中已知某些H F c具有適合用作用於氣溶膠投藥 推進劑的性質。舉例而言,公開歐洲專利申請案第〇 372 777 喊卿 089312270.5)描述1,1,1,2-四氟乙燒(111?(:_134^與 至;一種佐劑"(比HFC-134(a)具有更高極性之化合物)及 113089.doc 200800141 表面活性劑組合來製備適用於經氣溶膠路徑投藥之藥物懸 浮液及溶液調配物的用途。 同樣,PCT公開申請案第 WO 91/11496 號(PCT/EP91/00178) 揭示1,1,1,2,3,3,3_七氟丙烷(HFC-227)(視情況與其他推進 劑組份混合)用於製備藥物之懸浮液氣溶膠調配物的用 途。US-A-2 868 641及US-A-3 282 781揭示含有藥物(腎上 腺素或異丙基腎上腺素HC1)、共溶劑、推進劑及作為抗氧 化劑之抗壞血酸的氣溶膠組合物。歐洲專利673 240 B 1建議 將酸添加至醫學氣溶膠調配物以提供藥物穩定性。 美國申請案2002/0002204描述穩定的經包裝水性調配物 舒喘寧(albuterol)或其醫藥學上可接受之鹽。 然而,未描述US 2002/0002204之上述組合物或調配物之 一者在加壓MDI中之用途。熟習此項技術者已知用於醫藥 用途之MDI溶液調配物中之鹽因缺乏良好溶解度而難於處 理。尤其未揭示特定氣溶膠溶液調配物中之沙丁胺醇鹽在 加壓MDI中之用途。 【發明内容】 本發明提供一種穩定氣溶膠溶液調配物,其含有沙丁胺 醇酸加成鹽及可能的一種或數種其他藥用活性物質、HFC 推進劑、共溶劑及無機或有機酸。該調配物適用於以包含 多劑量之調配物之加壓MDI投藥。 【實施方式】 術語"氣溶膠溶液調配物"意謂適用於氣溶膠投藥之藥物 的醫藥調配物,其中藥物及賦形劑完全溶解。 113089.doc 200800141 術語”穩定的氣溶膠溶液調配物”意謂隨時間顯示大體上 化學穩定性之氣溶膠溶液調配物。調配物中之酸藉由使藥 物與浴液调配物中存在之共溶劑及/或水發生交互作用來 提供穩定性。 本發明之氣溶膠溶液調配物較佳包含〇_〇〇1至1〇%、較佳 0.01至0.5%、更佳0.05至〇.3%之沙丁胺醇。濃度係指游離沙 丁胺醇驗。 藥理學上可接受之酸的酸加成鹽中,可形成之鹽為選自 由鹽酸鹽、氫溴酸鹽、氫碘酸鹽、磷酸(氫)鹽、曱磺酸(氫) 鹽、硝酸(氫)鹽、順丁稀二酸(氫)鹽、醋酸(氫)鹽、苯曱酸(氫) 鹽、檸檬酸(氫)鹽、反丁烯二酸(氫)鹽、酒石酸(氫)鹽、&草 酸(氫)鹽、琥珀酸(氫)鹽及對甲苯磺酸(氫)鹽組成之群的鹽。 本發明之調配物中之沙丁胺醇酸加成鹽較佳$鹽酸鹽或 擰檬酸鹽,其分別為沙丁胺醇與鹽酸、沙丁胺醇與檸檬酸 之加成物。 沙丁胺醇與擰檬酸之加成產物可藉由用沙丁胺醇鹼轉化 擰檬酸來合成。所得產物由一或多個以下式Ia、此及/或^ 之化合物組成: 式la之化合物,
其為檸檬酸單沙丁胺醇。 式lb之化合物, 113089.doc 200800141
其為擰檬酸二沙丁胺醇。 式Ic之化合物,
其為檸檬酸三沙丁胺醇。 沙丁胺醇鹼與鹽酸之反應所得產物為式Ila之化合物
其為鹽酸沙丁胺醇。 若使用鹽酸沙丁胺醇,則上述量對應於〇 〇〇115至ι.115〇/0 之鹽酸沙丁胺醇、較佳〇 〇 115至0.575%、更佳0.0575至 0.345%之鹽酸沙丁胺醇。 右使用杯棣酸沙丁胺醇,則上述量對應〇 〇〇18至18%之 捧樣酸沙丁胺醇、較佳〇·〇1 8至〇·9%、更佳〇 〇9至〇·54%之檸 檬酸沙丁胺醇。 本發明之調配物可白冬盆# m田、、本α & 匕3 /、他条用活性物質或物質混合 物,較佳係選自以下群組·· 113089.doc 200800141 抗膽鹼劑: 抗膽驗劑較佳係選自由嗟托銨(tiotropium)、°塞托漠錢 (tiotropiumbromide)、氧托漠銨(oxitropiumbromide)、氟托 溴銨(flutropiumbromide)、異丙托溴銨(ipratropiumbromide)、 * 乙二醇°比洛銨鹽(glycopyrroniumsalt)、托氯銨 (trospiumchloride)、托特羅定(toiterodin)、2,2-二苯基丙酸 托品酯-甲溴化物、2,2-二苯基丙酸茛菪品酯-甲溴化物、2-氟基·2,2-二苯基酸性酸茛菪品酯-甲溴化物、2-氟基-2,2-二 ⑩ 苯基酸性酸托品酯-甲溴化物、3,3,,4,4,-四氟二苯基乙二酮 酸托品酯-甲溴化物、3,3’,4,4,-四氟二笨基乙二酮酸茛菪品 西旨-甲澳化物、4,4 - ^一氟二苯基乙二酮酸托品醋-甲漠化物、 4,4’-二氟二苯基乙二酮酸茛菪品酯-甲溴化物、3,3,_二氟二 苯基乙二酮酸托品酯-甲溴化物、3,3,-二氟二苯基乙二酮酸 茛菪品酯-曱溴化物、9-羥基-苐基-9-碳酸托品酯-甲溴化 物、9-氟基-苐基-9-碳酸托品酯-甲溴化物、9_羥基-苐基! 碳酸茛菪品酯-曱溴化物、9-氟基·莽基·9-碳酸茛菪品酯-曱 溴化物、9-甲基-第基_9_碳酸托品酯·甲溴化物、9-曱基-第 基_9_碳酸茛菪品酯-曱溴化物、二苯基乙二酮酸環丙基托品 • 酯-甲溴化物、2,2-二苯基丙酸環丙基托品酯-甲溴化物、9- . 羥基山基-9-碳酸環丙基托品酯-甲溴化物、9-曱基-第基-9- 碳酸環丙基托品酯-甲溴化物、9-甲基-P山基-9-破酸環丙基托 品酯-曱溴化物、9-羥基-第基·9_碳酸環丙基托品酯-曱溴化 物、4,4*-二氟二苯基乙二酮酸甲基酯環丙基托品酯_甲溴化 物、9_羥基-咄基-9-碳酸托品酯_甲溴化物、9_羥基-咄基 113089.doc •11- 200800141 碳酸茛菪品酯-甲溴化物、9-甲基-咄基-9-碳酸托品酯-甲溴 化物、9-甲基-咄基-9-碳酸茛菪品酯-甲溴化物、9-乙基-口山 基-9·碳酸托品酯-甲溴化物、9-二氟曱基-咄基-9-碳酸托品 酯-甲溴化物、9_羥甲基-咄基-9-碳酸茛菪品酯-甲溴化物組 成之群,視情況為外消旋體、對映異構物、非對映體之形 式及視情況其藥理學上可接受之酸加成鹽、溶劑合物及/或 水合物。 P-擬交感神經藥: β-擬交感神經藥較佳係選自由舒喘甯、班布特羅 (bambuterol)、比托特羅(bitolterol)、漠沙特羅(broxaterol)、 卡布特羅(carbuterol)、克余特羅(clenbuterol)、非諾特羅 (fenoterol)、福莫特羅(formoterol)、海索那林(hexoprenaline)、 異丁特羅(ibuterol)、因達卡特羅(indacaterol)、新異丙腎上 腺素、異丙腎上腺素、左沙丁胺醇(levosalbutamol)、馬布 特羅(mabuterol)、美盧君(meluadrine)、間經異丙腎上腺素、 奥西那林(orciprenaline)、°比布特羅(pirbuterol)、丙卡特羅 (procaterol)、瑞普特羅(reproteroi)、利米特羅(dmiterol)、 利托君(ritodrine)、沙美特羅(salmeterol)、曱氧苯舒喘寧 (salmefamol)、所特來諾(soterenot)、石黃特羅(sulphonterol)、 嗟拉米特(tiaramide)、間經叔丁腎上腺素、吐魯布特羅 (tolubuterol)> CHF-103 5 >HOKU-81 - KUL-1248- 3-(4-{6-[2-罗里基- 2-(4 -經基-3-經曱基-苯基)-乙基胺基]-己氧基}-丁基)_ 苯磺醯胺、5·[2·(5,6-二乙基-節·2·基胺基)-1-羥基-乙基]-8-羥基-1//·喹啉-2-酮、4-羥基-7_[2·{[2-{[3-(2-苯基乙氧基) 113089.doc -12- 200800141 丙基]磺醯基}乙基]-胺基丨乙基]_2(3Η)_苯幷噻唑酮、^(2· 氟基-4-羥苯基)-2-[4-(l-苯幷咪唑基甲基_2_ 丁基胺基] 乙醇、W3-(4-甲氧基苯基-胺基)_4_經苯基]-2-[4-(1-苯幷口米 唑基)-2-甲基-2- 丁基胺基]乙醇、羥基-%氧代 -4H-1,4-苯幷嗔嗪_8-基HKRN-:曱基胺基苯基)冬 曱基-2-丙基胺基]乙醇、羥基_3·氧代·-苯幷 噁嗪-8-基:1-243-(4-曱氧基苯基)_2_甲基_2-丙基胺基]乙 醇、1-[2Η·5-羥基-3_氧代-4Η-1,4·苯幷噁嗪_8-基卜2-[3-(4-正丁乳基笨基)-2-甲基-2-丙基胺基]乙醇、經基_3_ 氧代-4H-1,4-本幷°惡嘻-8-基]_2·{4-[3-(4甲氧基苯 基)-1,2,4-三唑-3·基]-2-甲基_2_丁基胺基}乙醇、羥基_8_ (1-羥基-2-異丙基胺基丁基)-2Η-1,4-苯幷噁嗪_3·(4Η)-酮、 1-(4-胺基-3 -氣基-5-二氟曱基苯基)_2·第三丁基胺基)乙醇 及1-(4-乙氧基羰基胺基-3-氰基-5 -氟苯基)-2-(第三丁基胺 基)乙醇組成之群’視情況為外消旋體、對映異構物、非對 映體之形式及視情況其藥理學上可接受之酸加成鹽、溶劑 合物及/或水合物。 甾類: 甾類較佳係選自由潑尼龍(prednisolone)、潑尼松 (prednisone)、布替可特丙酸醋(butixocortpropionate)、 RPR-106541 、氟尼縮松(flunisolide)、倍氣米松 (beclomethasone)、曲安奈德(triamcinolone)、布地縮松 (budesonide)、氣替卡松(fluticasone)、莫美他松(mometasone)、 環索奈德(ciclesonide)、羅氣烧(rofleponide)、ST-126、地 113089.doc -13- 200800141 塞米松(dexamethasone)、6oc,9oc-二氟基·17α·[(2_呋喃羰基) 氧基]-11β-羥基-16β-甲基-3-氧代·雄固_ι,4-二烯_17β·硫代 碳酸(S)-氟甲基酯、6α,9α-二氟基-ΐΐβ_羥基_16…曱基_3_氧 代-17α-丙醯氧基-雄固_1,4_二烯_ ΐ7β-硫代碳酸(s)_(2_氧代_ 四氫-吱喃-3S-基)醋及etiprednol-二氣醋酸酯(BNp]66)組 成之群,視情況為外消旋體、對映異構物、非對映體之形 式及視情況其藥理學上可接受之酸加成鹽、溶劑合物及/或 水合物。 PDEIV-抑制劑: PDEIV-抑制劑較佳係選自由恩普法林(enpr〇fyiHn)、塞法 林(theophyllin)、羅氟司特(roflumilast)、阿裏夫羅(arifl〇)(西 洛司特(。11〇111以3〇)、€?-325,366、:8丫343、0-4396(8^1- 35 1591)、AWD-12-28 l(GW-842470)、N-(3,5-二氯-l-氧代- "比咬-4-基)-4-二氟甲氧基_3_環丙基甲氧基苯甲醯胺、 NCS-613、帕瑪紛^j(pUmafentine)、㈠?-[(4认*,1〇七8*)-9- 乙氧基- l,2,3,4,4a,l 〇b-六氫·8_甲氧基-2-甲基苯幷[s][l,6] 峰唆-6-基]-N,N-二異丙基苯甲醯胺、(RH+pw心溴苯 基)-4-[(3·環戊基氧基)甲氧基苯基>2_σ比咯啶酮、3彳環戊 基氧基-4-甲氧基笨基)-]μ(4_Ν,-[Ν-2-氰基-s_曱基-異硫脲 基]节基)-2-。比咯啶酮、順[4_氰基環戊基氧基甲氧 基苯基)環己-1-碳酸]' 2-羰基甲氧基-4-氰基-4-(3-環丙基甲 氧基-4-二氟基曱氧基苯基)環己-^酮、順[4-氰基_4_(3_環丙 基曱氧基-4-二氟甲氧基苯基)環己-;[_醇]、(R)_(+)i乙基 [4-(3-環戊基氧基_心甲氧基苯基)亞吼咯啶_2_基]醋酸酯、 113089.doc -14- 200800141 (S)-(·)·乙基[4-(3-環戊基氧基-4-甲氧基苯基)吼咯啶-2-亞 基]醋酸酯、CDP840、Bay-198004、D-4418、PD-168787、 T-440、T-25 85、阿羅法林(arofyllin)、阿替佐拉姆 (atizoram)、V-11294A、Cl-1018、CDC-801、CDC-3052、 D-22888、YM-58997、Z-15370、9-環戊基-5,6_ 二氫-7-乙基-3_(2-噻吩基)-911-二氫吡唑[3,4-(:]-1,2,4-三唑[4,34]吡啶及 9-¾戍基-5,6 -二氯·7·乙基-3-(第三丁基)-911-二鼠°比嗤 [3,4-c]-l,2,4-三唑[4,3-a]吡啶組成之群,視情況為外消旋 體、對映異構物、非對映體之形式及視情況其藥理學上可 接受之酸加成鹽、溶劑合物及/或水合物。 LTD4-拮抗劑: LTD4-拮抗劑較佳係選自由孟魯司特(montelukast)、 l-(((R)-(3-(2-(6,7-二氟基-2-喹啉基)乙烯基)苯基)-3-(2-(2-羥基-2-丙基)苯基)硫代)甲基環丙烷-酸性酸、l-(((l(R)-3(3-(2_(2,3-二氯基噻吩幷[3,2-b]吼啶-5-基)·(Ε)_乙烯基)苯 基)-3-(2-(1-羥基·1-甲基乙基)苯基)丙基)硫代)甲基)環丙烷 酸性酸、普命司特(pranlukast)、紮魯司特(zafirlukast)、 [2-[[2-(4-第三丁基-2-噻唑基)-5-苯幷呋喃基]氧基甲基]苯 基]酸性酸、MCC-847(ZD-3523)、MN-001、MEN-91507 (LM-1507)、VUF-5078、VUF-K_8707 及 L-733321 組成之群, 視情況為外消旋體、對映異構物、非對映體之形式及視情 況其藥理學上可接受之酸加成鹽、溶劑合物及/或水合物。 EGFR-激酶抑制劑: 西妥昔單抗(cetuximab)、曲妥珠單抗(trastuzumab)、 113089.doc -15- 200800141 ABX-EGF、Mab ICR-62、4·[(3-氯-4'氟苯基)胺基;ϋ{[4·(嗎 啉-4-基)-1-氧代-2-丁烯-1-基]胺基}-7-環丙基曱氧基·喳唑 琳、4_[(R)-(1-苯基乙基)胺基]-6-{[4-(嗎琳-4-基)_ι·氧代2 丁 ~ -1 -基]胺基} -7-環戊基氧基-喧嗤琳、4- [(3-氯·4_氣笨 基)胺基]-6_{[4-((R)-6-甲基-2-氧代-嗎啉_4_基)_丨_氧代^ 丁烯-1-基]胺基}-7-[(S)_(四氫吱喃-3-基)氧基]•喹唾琳、 4-[(3_氯_4·氟-苯基)胺基]-6-[2_((S)_6·甲基_2_氧代_嗎琳_4· 基)-乙氧基]-7-甲氧基-喹唑啉、4·[(3-氣-4-氟苯基)胺 基卜6-({4-[Ν-(2·曱氧基-乙基)-Ν-甲基-胺基]小氧代_2_ 丁 烯-l-基}胺基)-7-環丙基甲氧基-喧哇琳、苯義乙 基)胺基]-6-({4-[N-(四氫哌喃-4-基)甲基·胺基]_〗·氧代 2-丁烯-l-基}胺基)_7_環丙基甲氧基_喹唑啉、4_[(3_氯_4氟 苯基)胺基]-6-({4-[N-(2-甲氧基-乙基)_Ν•甲基_胺基氧 代·2-丁-l-基}胺基)-7·環戊基氧基-喹唑啉、4_[(3_氯·心氟苯 基)胺基]-6-{[4-(Ν,Ν·二甲基胺基)_!_氧代丁烯基]胺 基卜了^…气四氫呋喃_2_基)甲氧基]_喹唑啉、4_[(3_乙炔基_ 苯基)胺基]-6,7-雙-(2-甲氧基_乙氧基)_喹唑啉、 苯基-乙基)胺基]-6-(4-羥基-苯基)-7Η-吡咯幷[2,3_d]嘧啶、 基)-1-氧代-2-丁烯-1-基]胺基卜7-乙氧基-苯基- '喹啉、‘[(RXb
基卜7-[(四氫呋喃_2•基)甲氧基]_喹唑啉、心[(3-乙炔基-苯 3氰基-4_[(3-氣-4-氟苯基)胺基]-6_{[4·(Ν,Ν•二甲基胺 氧代-2 基)胺 113089.doc -16 - 200800141 基)月女基]-6-{[4-(5,5-二曱基-2·氧代-嗎琳基)_卜氧代·2_ 丁烯_1_基]胺基卜喹唑啉、4-[(3·氯-4-氟-苯基)胺基]-6-{2-[4-(2-氧代-嗎琳-4-基)-娘咬-1-基]_乙氧基}_7_曱氧基-喹唑啉、4-[(3-氣-4-氟-苯基)胺基]-6-(反-‘胺基_環己,卜基 氧基)-7-甲氧基-喹唑啉、4-[(3-氯-4_氟·苯基)胺基]·6·(反_4_ 甲烧磺醯基胺基-環己-1-基氧基)·7_曱氧基_啥嗤淋、4-[(3-氣-4-氟-苯基)胺基]·6-(四氫哌喃-3-基氧基)_7_甲氧基-喹唑 琳、4-[(3-氯-4-氟-苯基)胺基]-6_{1-[(嗎啉_4_基)戴基]-哌。定· 4-基氧基}-7-甲氧基-喹唑啉、4-[(3-氣-4-氟-苯基)胺 基]-6-(旅啶-3-基氧基)-7-甲氧基-喹唑啉、4-[(3-氣-4-氟-苯 基)胺基]_ 6-[1-(2-乙醢胺基-乙基)-旅咬_4_基氧基]-7-曱氧 基-喹唑啉、4-[(3·氯-4-氟-苯基)胺基]-6-(四氫哌喃-4-基氧 基)-7-乙氧基-喹唑啉、4-[(3-氯-4-氟-苯基)胺基]-6-{反-4-[(嗎啉-4-基)羰基胺基]-環己_1_基氧基卜7_甲氧基-喹唑啉、 4-[(3 -氯-4-氟-苯基)胺基]·6-{ 1·[(旅咬-1-基)羰基]-派啶-4· 基氧基卜7-曱氧基-喹唑啉、4_[(3_氣-4-氟-苯基)胺基]-6-(順-4-{N-[(嗎啉-4-基)羰基]-N-曱基-胺基卜環己-1-基氧基)-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)胺基]-6-(反-4-乙烷磺 醯基胺基-環己-1_基氧基)-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)胺基]-6-( 1 -甲烷磺醯基-哌啶-4-基氧基)-7-(2-曱氧基_ 乙氧基)-啥嗤琳、4-[(3 -氯-4-氣-苯基)胺基]_6-[1-(2 -甲氧基_ 乙醯基)-哌啶-4-基氧基]-7-(2-甲氧基-乙氧基)-喹唑啉、4-[(3-乙炔基-苯基)胺基]_6_(四氫派喃-4-基氧基)-7-甲氧基_ 口圭嗤琳、4 -[(3 -氣-4-氣-苯基)胺基]-6-(順-4-{N-[(派11定-1 -基) 113089.doc -17· 200800141 羰基]-Ν-甲基-胺基卜環己-1-基氡基)·7_甲氧基_喹唑啉、 4-[(3-氯-4-氣-苯基)胺基]-6-{順-4,嗎啉^^基)羰基胺基卜 環己-1-基氧基}-7·曱氧基-喧唾琳、4_[(3_氣_4_氟_苯基)胺 基]·6-{1-[2-(2-氧代处咯啶-1-基)乙基]•哌啶_心基氧基卜7_ 甲氧基-喹唑啉、4-[(3-乙炔基-苯基)胺基]_6·(1_乙醯基_哌啶_ 4-基氧基)-7-甲氧基-噎嗤琳、4_[(3_乙炔基-苯基)胺 基]-6-(1-甲基-派咬-4-基乳基)-7-甲氧基·啥嗤琳、4-[(3_乙 炔基-苯基)胺基]-6-(1 -甲烧石黃醢基-旅咬基氧基)-7-甲氧 基-喧嗤淋、4-[(3-氣-4-氟-苯基)胺基]·6-(ι_曱基-旅咬-4-基 氧基)-7(2-甲氧基-乙氧基)-喹唑啉、4-[(3_乙炔基_苯基)胺 基]-6-{ 1-[(嗎啉-4-基)羰基]-哌啶-4-基氧基卜7-甲氧基-喹 唑啉、4-[(3-氣-4-氟-苯基)胺基]-6-{1-[(]^甲基-:^-2-甲氧基 乙基-胺基)毅基]-派唆-4-基氧基}-7·甲氧基_嗜嗤琳、4-[(3-氯-4-氟-苯基)胺基]-6-( 1-乙基-哌啶-4-基氧基)-7-甲氧基· 喹唑啉、4-[(3·氯-4-氟-苯基)胺基]-6-[順-4-(N-甲烷磺醯基-N-曱基-胺基)-環己-1-基氧基]-7-甲氧基-喹唑啉、4-[(3-氣· 4-氟-苯基)胺基]-6-[順-4-(N-乙醯基甲基·胺基)_環己-1 基氧基]-7-甲氧基-喹唑啉、4-[(3-氣-4_氟_苯基)胺基]_6_(反_ 4-甲基胺基·環己-1-基氧基)-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)胺基]-6·[反-4-(N-曱烷磺醯基甲基-胺基)-環己· 1-基氧基]-7-甲氧基-喹唑啉、4-[(3-氯-4-氟-苯基)胺 基]-6-(反-4-二甲基胺基-環己-1-基氧基)-7·甲氧基-喹唑啉、 4_[(3·氯-4-氟苯基)胺基]-6-(反·4-{Ν_[(嗎啉·4·基)羰基]·Ν_ 曱基-胺基卜環己-1-基氧基)-7-甲氧基-喹唑啉、4-[(3-氣-4- 113089.doc •18· 200800141 氤-苯基)胺基]-642-(2,2-二曱基氧代-嗎啉_4·基)-乙氧 基]-7-[(S)-(四氫呋喃-2-基)曱氧基]•喹唑琳、4-[(3-氯-4-1-本基)胺基]-6-(1-曱烧石黃醢基-旅咬-4-基氧基)·7-曱氧基-啥 吐琳、4-[(3-氯-4-氟-苯基)胺基]-6-(1-氰基-哌啶-4-基氡 基)-7-甲氧基-喹唑啉及4-[(3-氯-4-氟-苯基)胺基]-6-{l-[(2-曱氧基乙基)羰基]-哌啶-4-基氧基}-7-甲氧基-喹唑啉,視情 況為外消旋體、對映異構物、非對映體之形式及視情況其 藥理學上可接受之酸加成鹽、溶劑合物及/或水合物。 此外 4 化合物可來自 β-niimetika、antiallergika、 ergotalcaloid衍生物、三曱基丁烷、CGRp_拮抗劑、磷酸二 酉曰酶-V-抑制劑之群,視情況為外消旋體、對映異構物、非 對映體之形式及視情況其藥理學上可接受之酸加成鹽、溶 劑合物及/或水合物。 該兩個提及之沙丁胺醇之鹽(鹽酸沙丁胺醇或檸檬酸沙 丁胺醇)之一者較佳與上文引用之一或多種其他藥用活性 物夤連同作為推進劑之環境上安全之氫氟碳(HFc)、作為共 /合d之有機化合物及無機酸或有機酸組合以氣溶膠溶液調 配物使用。 在此組合中更佳將異丙托銨用作藥用活性物質。 合適HFC推進劑為當與共溶劑混合形成均質推進劑系統 (其中可溶解治療有效量之藥物)之彼等。hfc推進劑必須為 f理子上安王的且必須具有適合於使藥物經由加壓訄以投 藥之蒸氣壓。料,HFC推進劑必須與將投錢物之讓 裝置(諸如容H、閥及密封墊#等)之元件相容。較佳紙 113089.doc •19- 200800141 推進劑為 1,1,1,2-四氟匕烷(HFC-134(a))(HFC-134(a))及 1,1,1,2,3,3,3-七氟丙烧(HFC-227)。HFC -134(a)尤其較佳。 HFC推進劑之其他實例為HFC-32(二氟曱烷)、HFC-143(a) (1,1,1_三氟乙烧)、11?0134(1,1,2,2_四氟乙烧)及1^(^-1523 (1,1-二氟乙烷)。 熟習此項技術者應瞭解在本發明中可使用非鹵代烴推進 劑代替HFC推進劑。非鹵代烴之實例為包括丙烷、正丁烷 及異丁烷之飽和烴類及包括二乙醚之醚類。 熟習此項技術者亦應瞭解雖然較佳使用單一 HFC推進 劑’但是兩種或兩種以上HFC推進劑之混合物或至少一種 HFC推進劑與一或多種非CFC推進劑之混合物可用於本發 明之氣溶膠溶液調配物中。 主要由於藥物與共溶劑及/或存在於溶液調配物中之水 之交互作用,因此調配物中之酸提供抗藥物降解或分解之 穩定性。酸可為無機或有機酸。 無機或礦物酸之實例為鹽酸、硫酸、硝酸或填酸或其類 似物。無機酸更佳為鹽酸。 或者,酸係選自熟習此項技術者已知之酸(如有機酸)之 群’在大多數狀況下認為其相對於無機酸為弱酸。該群之 代表及本發明中較佳者為抗壞血酸、擰檬酸、乳酸、蘋果 西文、苯甲酸及酒石酸。根據本發明,擰檬酸及抗壞血酸為 最佳有機酸。 本發明之调配物之特徵在於酸之濃度處於對應於水性溶 液中PH值範圍為mo之範圍。在本發明之較佳氣溶膠溶 H3089.doc -20- 200800141 液調配物中,之濃度處於對應於水性溶液中阳值範圍為 2.5-5.0、更佳3.0-4.5之範圍。
本發明之調配物可類比於此項技術已知之方法來製備。 若需要’醫藥學上可接受之賦形射引人本發明之氣溶 膠溶液調配物中。舉例而言’可添加可溶性表面活性劑以 改良用於雜物之氣溶膠投藥之M D以置中所使用之間門 系統的效能。較佳表面活性劑之實例為脫水山梨糖醇三油 酸醋、卵翻及十四⑽異丙ι此項技術巾熟知其他合 適潤滑劑(參見,例如公開歐洲專利申請案第〇372777號 (EPO 893122705))。#他賦形劑為:⑷例如抗壞血酸及生 育酴之抗氧化劑;(_如薄荷腦、甜味狀味覺掩蔽劑及 人工或天然香料;及⑷例如正戊烷、異戊烷、新戊烷及正 己炫之Μ力調節劑。 適用於本發明之調配物之共 丙醇及苄基醇之醇;例如丙 共溶劑較佳為有機化合物。 溶劑之實例為:例如乙醇、異 二醇、聚乙二醇、聚丙二醇、乙二醇醚之二醇及氧化乙烯 及氧化丙社嵌段絲物;及例如甘油、聚氧乙烯醇、聚 氧乙烯脂肪酸酯及聚乙二醇四氫呋喃甲基醚(例如聚乙二 醇四氫呋喃甲基醚75)之其他物質。 與藥物交互作用呈惰性之共溶劑之實例為例如正丙烷、 正丁烧、異丁烧、正戊炫、異戍燒、新戊燒及正己烧之煙 類及例如二乙岭之醚類。 發明較之佳共溶劑為乙基醇(乙醇)。 /、;谷之畺較佳在總組合物之5_5〇%(w/w)範圍内。更佳 113089.doc •21· 200800141 地,本發明之調配物中之共溶劑的量在10_4〇%(w/w)範圍 内、較佳在15-30%範圍内。 可將少量水添加至調配物以增強其對活性物質及賦形劑 之溶解力。除共溶劑外,較佳高達5%(w/w)之水、更佳高達 3°/〇及最佳高達2〇/〇之水用於含水調配物中。 本發明之另一較佳實施例係針對不含任何水之調配物。 在该等無水調配物中,共溶劑之量較佳在約 範圍内、較佳在約30_50%(w/w)範圍内。 本發明之調配物可用此項技術6知之包含μ量調配物 之吸入器(定劑量吸入器=MDI)投藥。 本發明之另-態樣係針將如上文所述氣溶膠溶液調配物 用於製造供治療呼吸㈣、尤其⑺P峨録塞性肺病)及 哮喘之藥物的用途。 本發明之又-態樣係針對用於治療尤其諸如c㈣(慢性 阻塞性肺病)‘或哮喘之呼吸疾病的方法,其特徵在於投與上 文所述.之氣溶膠溶液調配物。 本發明之另-態樣係針對-加壓定劑量吸人器,其特徵 在於該醫藥調配物含有酸加成沙丁胺醇鹽、HFC推進劑、 共溶劑及無機或有機酸。 以下實例用於進一步說明本發明而 ^ 明而非以舉例之形式將本 秦明之範疇侷限於下文提供之實施例中。 L調配物實例 113〇89.d〇c -22- 200800141
組份 濃度[% w/w] 檸檬酸沙丁胺醇 0.173 無水乙醇(USP) 30.000 水(經純化,USP) 2.000 檸檬酸(USP) 0.004 HFC-134a 67.823 組份 濃度[% w/w】 鹽酸沙丁胺醇 0.221 無水乙醇(USP) 30.000 水(經純化,USP) 2.000 擰檬酸(USP) 0.003 HFC-134a 67.777 組份 濃度【% w/w】 檸檬酸沙丁胺醇 0.173 單水合異丙托溴銨 0.021 無水乙醇(USP) 30.000 水(經純化,USP) 2.000 檸檬酸(USP) 0.004 HFC-134a 67.802 組份 濃度【% w/w】 擰檬酸沙丁胺醇 0.221 單水合異丙托溴铵 0.040 .無水乙醇(USP) 30.⑽ 0 水(經純化,USP) 2.000 檸檬酸(USP) 0.003 HFC434a 67.736 113089.doc -23- 200800141 組份 濃度【% w/w】 鹽酸沙丁胺醇 0.110 無水乙醇(USP) 40.000 水(經純化,USP) 2.000 檸檬酸(USP) 0.003 HFC-134a 57.888 E)— 組份 濃度[% w/w】 擰檬酸沙丁胺醇 0.173 單水合異丙托溴銨 0.021 無水乙醇(USP) 40.000 檸檬酸(USP) 0.004 HFC-134a 57.802 上述調配物可由此項技術中已知之習用方法製備。 F) II·鹽酸沙丁胺醇之製備: 邊攪拌邊將沙丁胺醇驗逐步添加至1:1 (w/w)之乙醇與二 乙醚混合物中直至形成30% w/w之溶液。將溶液冷卻至約 1 〇°C。隨後,在連續攪拌下將氣體鹽酸穿過該溶液,並冷 卻至約10t:。穿過該溶液之氣體鹽酸之總量應對應於沙丁 胺醇鹼之莫耳量之5倍。在已引入全部量之鹽酸氣體後,將 所得懸浮液冷卻至約〇°C。過濾出沉澱之鹽酸沙丁胺醇。隨 後將分離之殘餘物由乙醇再結晶兩次。 所得鹽酸沙丁胺醇為白色結晶粉末。熔點為 III·檸檬酸沙丁胺醇之製備 在周圍溫度下,邊攪拌邊將30% w/w檸檬酸於水中之溶 液添加至粉狀沙丁胺醇鹼於水中之懸浮液中。在沙丁胺醇 鹼已徹底溶解後,在周圍溫度下邊在攪拌邊將丙酮添加至 113089.doc -24- 200800141 該溶液中直至丙酮之比例總计達混合物之約80% w/w。隨後 將混合物冷卻至約〇。〇且將沉澱之檸檬酸沙丁胺醇濾出。將 分離之殘餘物由乙醇/乙酸乙酯70:30(w/w)之混合物再結晶 兩次0 ”1 TT 4宁你明c 7 I 脸95古口 > . 知呈白色晶體。其在大約13 3。〇下分解 熔融(由差示掃描熱量定 。下刀解 、竭始測疋,加熱速率i(rc/min)。 113089.doc -25-
Claims (1)
- 200800141 十、申請專利範圍: 1 · 一種氣溶膠溶液調配物,其含有酸加成沙丁胺醇鹽、hfc 推進劑、共溶劑及無機或有機酸。 2·如請求項1之氣溶膠溶液調配物,其特徵在於該調配物包 含0.001至1%之沙丁胺醇。 3. 如請求項1之氣溶膠溶液調配物,其特徵在於該沙丁胺醇 鹽為鹽酸鹽或擰檬酸鹽。 4. 如叫求項1之氣溶膠溶液調配物,其特徵在於該調配物包 含一或多種其他藥用活性物質。 5. 如請求項4之氣溶膠溶液調配物,其特徵在於該其他藥用 /舌性物質係來自抗膽驗劑、β_擬交感神經藥、留類、 PDEIV•抑制劑、LTD4_拮抗劑、EGFR·激酶抑制劑之群。 6 ·如明求項5之氣溶膠溶液調配物,其特徵在於該其他藥用 /舌性物質為異丙托(ipratropium)溴銨。 7 ·如清求項1至6中任一項之氣溶膠溶液調配物,其特徵在 於該調配物包含作為酸加成鹽之擰檬酸沙丁胺醇或鹽酸 沙丁胺醇’與作為其他藥用活性物質之異丙托溴銨組合。 8·如請求項1至6中任一項之氣溶膠溶液調配物,其特徵在 於該 HFC推進劑係選自 HFC-134(a)、HFC-227、HFC-32、 HFC-143(a)、HFC-134、HFC-152a及其混合物。 9·如請求項1至6中任一項之氣溶膠溶液調配物,其特徵在 於該酸係選自鹽酸、硫酸、硝酸或磷酸之無機酸。 10·如請求項1至6中任一項之氣溶膠溶液調配物,其特徵在 於該酸係選自抗壞血酸、檸檬酸、乳酸、蘋果酸、笨甲 113089.doc 200800141 酸或酒石酸之有機酸。 11. 12. 13. 14. 15. 如請求項1至6中任一項之氣溶膠溶液調配物,其特徵在 於其額外包含至高約5%之量之水。 如叫求項1至6中任一項之氣溶膠溶液調配物,其特徵在 於該共溶劑為有機化合物。 月求員1至6中任一項之氣溶膠溶液調配物,其特徵在 於其包含作為共溶劑之醇、乙二醇、乙二醇_、氧化乙 烯二氧化丙烯之嵌段共聚物、甘油、聚氧乙烯醇、聚氧 乙=月日肪酸_或聚乙二醇四氫β夫喃甲基_ (办⑶如仏)。 如清求項1至6中任—項之氣溶膠溶液調配物 於其不含水。 :::::至6中任一項之氣溶膠溶液調配物,其特徵在 於该八 >谷劑以5-50%(w/w)範圍内之量存在。 其特徵在 16· 17·一種如請求項1至丨5中任一項 一加壓定劑量吸入器的用途。 之氣溶膠溶液調配物 用於 用於 18· 一種式la之化合物,19. 一種式lb之化合物,la 113089.doc 20080014120. —種式Ic之化合物,2 1 · —種含有氣溶膠溶液形式之多劑量醫藥調配物的加壓定 劑量吸入器,其特徵在於該醫藥調配物含有沙丁胺醇之 酸加成鹽、HFC推進劑、共溶劑及無機或有機酸。 22.如請求項21之加壓定劑量吸入器,其特徵在於該沙丁胺 醇鹽可為鹽酸鹽或檸檬酸鹽。 23·如請求項21之加壓定劑量吸入器,其特徵在於該調配物 額外包含異丙托漠銨。 24·如請求項21至23中任 項之加壓定劑量吸入器,其特徵 在於該調配物包含作為酸成 风1<知棣酸沙丁胺醇或鹽 之異丙托溴銨組合 酸沙丁胺醇,與作為藥用活性物質 113089.doc 200800141 七、指定代表圖: (一) 本案指定代表圖為:(無) (二) 本代表圖之元件符號簡單說明: 八、本案若有化學式時,請揭示最能顯示發明特徵的化學式:113089.doc
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05017599 | 2005-08-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200800141A true TW200800141A (en) | 2008-01-01 |
Family
ID=35564491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095129480A TW200800141A (en) | 2005-08-12 | 2006-08-11 | HFC solution formulations containing salbutamol hydrochloride or salbutamol citrate |
Country Status (6)
Country | Link |
---|---|
US (1) | US20070041911A1 (zh) |
AR (1) | AR057745A1 (zh) |
PE (1) | PE20070353A1 (zh) |
TW (1) | TW200800141A (zh) |
UY (1) | UY29740A1 (zh) |
WO (1) | WO2007020204A2 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0501956D0 (en) * | 2005-01-31 | 2005-03-09 | Arrow Internat | Nebulizer formulation |
GB201108039D0 (en) | 2011-05-13 | 2011-06-29 | Mexichem Amanco Holding Sa | Compositions |
GB201117619D0 (en) | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
GB201117621D0 (en) | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
GB201306984D0 (en) | 2013-04-17 | 2013-05-29 | Mexichem Amanco Holding Sa | Composition |
WO2017093758A1 (en) | 2015-12-04 | 2017-06-08 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
CN109715148A (zh) | 2016-09-19 | 2019-05-03 | 墨西哥氟石股份公司 | 药物组合物 |
ES2892673T3 (es) | 2016-09-19 | 2022-02-04 | Mexichem Fluor Sa De Cv | Composición farmacéutica que comprende glicopirrolato |
MX2019003105A (es) | 2016-09-19 | 2019-08-01 | Mexichem Fluor Sa De Cv | Composicion farmaceutica. |
WO2019236559A1 (en) * | 2018-06-04 | 2019-12-12 | Lupin Inc. | Stable pharmaceutical compositions for pressurized metered dose inhalers |
FR3130554A1 (fr) | 2021-12-20 | 2023-06-23 | Aptar France Sas | Composition pharmaceutique comprenant du salbutamol |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8828477D0 (en) * | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
ATE203900T1 (de) * | 1991-06-10 | 2001-08-15 | Schering Corp | Fluorchlorkohlenwasserstofffreie aerosolformulierungen |
JP2003221335A (ja) * | 2001-10-26 | 2003-08-05 | Dey Lp | 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法 |
CN1216600C (zh) * | 2002-04-24 | 2005-08-31 | 信谊药厂 | 盐酸左旋沙丁胺醇气雾剂及制备工艺 |
CN1228045C (zh) * | 2003-11-03 | 2005-11-23 | 王立强 | 口腔速崩速溶片制剂及其制备方法 |
GB0406069D0 (en) * | 2004-03-17 | 2004-04-21 | Thompson James | Process |
-
2006
- 2006-08-04 WO PCT/EP2006/065090 patent/WO2007020204A2/en active Application Filing
- 2006-08-09 US US11/463,477 patent/US20070041911A1/en not_active Abandoned
- 2006-08-10 PE PE2006000973A patent/PE20070353A1/es not_active Application Discontinuation
- 2006-08-11 TW TW095129480A patent/TW200800141A/zh unknown
- 2006-08-11 AR ARP060103518A patent/AR057745A1/es not_active Application Discontinuation
- 2006-08-11 UY UY29740A patent/UY29740A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20070041911A1 (en) | 2007-02-22 |
UY29740A1 (es) | 2007-03-30 |
PE20070353A1 (es) | 2007-04-19 |
WO2007020204A2 (en) | 2007-02-22 |
WO2007020204A3 (en) | 2007-06-07 |
AR057745A1 (es) | 2007-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200800141A (en) | HFC solution formulations containing salbutamol hydrochloride or salbutamol citrate | |
TWI377943B (en) | Aerosol suspension formulations containing tg 227 ea as propellant | |
TW200800294A (en) | Pharmaceutical composition for aerosols with two or more active substances and at least one surfactant | |
ES2774391T3 (es) | Composiciones, métodos y sistemas para la administración respiratoria de dos o más agentes activos | |
AU2005315337B2 (en) | Pharmaceutical compounds and compositions | |
JPH11510150A (ja) | 長期間持続性作用を有する臭化イプラトピウムエナンチオマー | |
AU2006275137A1 (en) | Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation | |
KR20080024532A (ko) | 신규한 티오트로퓸 염의 제조방법, 신규한 티오트로퓸 염및 이의 약제학적 조성물 | |
NZ530929A (en) | Compositions of fine solid particles of selective PDE4 inhibitors for delivery to the lungs by inhalation | |
TW200815059A (en) | Dosage aerosols for the application of pharmaceutical formulations | |
EP4175620B1 (en) | Compositions, methods and systems for aerosol drug delivery | |
ZA200704378B (en) | Pharmaceutical compounds and compositions | |
TW200400036A (en) | New pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | |
US20060120972A1 (en) | 9-(N-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension | |
AU2013368298B2 (en) | Methods and compositions for administration of oxybutynin | |
KR20230052903A (ko) | 흡입 투여를 위한 병용 요법 | |
EP1655027A1 (en) | 9-(N-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension and migraine |